PLAU和LAMC2可以预测HNSCCCC患者的预后不佳
Zhi-Chen Guo1,2,3, Si-Li Jing4, Hao Cui1,2,3
1Key Laboratory of Shanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, China.
Journal of Cancer
|June 16, 2023
概括
这项研究确定了PLAU和LAMC2作为头部和部状细胞癌 (HNSCC) 的关键基因. 它们的表达增加与预后不佳相关,这表明它们是HNSCC患者有价值的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 头部和部状细胞癌 (HNSCC) 是一种流行癌症,但其潜在的分子驱动因素仍然不完全理解.
- 识别新的分子机制对于改善HNSCC诊断和治疗策略至关重要.
研究的目的:
- 阐明HNSCC发展的分子机制.
- 为了确定HNSCC患者的潜在预后生物标志物.
主要方法:
- 利用癌症基因组图谱 (TCGA) 和GSE23036数据集来识别差异表达基因 (DEG).
- 应用权重基因同表达网络分析 (WGCNA) 寻找与瘤状况相关的基因模块.
- 在患者样本上使用人类蛋白质图谱 (HPA),GEPIA,免疫组织化学 (IHC) 和免疫光 (IF) 验证基因表达和预后意义.
主要成果:
- WGCNA确定了24个正相关基因和15个负相关基因与瘤状态.
- 确定PLAU和LAMC2与HNSCC患者的预后不佳有显著关联.
- 175个HNSCC样本的免疫组织化学证实PLAU和LAMC2表达与预后不佳相关,并且显示了这两种基因之间的正相关性.
结论:
- 在HNSCC组织中,PLAU和LAMC2表达是正相关的.
- PLAU和LAMC2可以作为头部和部状细胞癌的独立预后生物标志物.
相关概念视频
lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402


